STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice

Zili Wang, Esteban Celis

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Therapeutic vaccines to induce anti-tumor CD8 T cells have been used in clinical trials for advanced melanoma patients, but the clinical response rate and overall survival time have not improved much. We believe that these dismal outcomes are caused by inadequate number of antigen-specific CD8 T cells generated by most vaccines. In contrast, huge CD8 T cell responses readily occur during acute viral infections. High levels of type-I interferon (IFN-I) are produced during these infections, and this cytokine not only exhibits anti-viral activity but also promotes CD8 T cell responses. The studies described here were performed to determine whether promoting the production of IFN-I could enhance the potency of a peptide vaccine. We report that cyclic diguanylate monophosphate (c-di-GMP), which activates the stimulator of interferon genes, potentiated the immunogenicity and anti-tumor effects of a peptide vaccine against mouse B16 melanoma. The synergistic effects of c-di-GMP required co-administration of costimulatory anti-CD40 antibody, the adjuvant poly-IC, and were mediated in part by IFN-I. These findings demonstrate that peptides representing CD8 T cell epitopes can be effective inducers of large CD8 T cell responses in vaccination strategies that mimic acute viral infections.

Original languageEnglish (US)
Pages (from-to)1057-1066
Number of pages10
JournalCancer Immunology, Immunotherapy
Volume64
Issue number8
DOIs
StatePublished - Aug 28 2015

Fingerprint

Subunit Vaccines
Melanoma
T-Lymphocytes
Virus Diseases
Neoplasms
Vaccines
CD8 Antigens
Interferon Type I
Experimental Melanomas
T-Lymphocyte Epitopes
Interferons
Anti-Idiotypic Antibodies
Vaccination
Survival Rate
Clinical Trials
Cytokines
Peptides
Infection
Genes

Keywords

  • CD8 T cells
  • Immunotherapy
  • Peptide vaccines
  • STING
  • Type-I interferon

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. / Wang, Zili; Celis, Esteban.

In: Cancer Immunology, Immunotherapy, Vol. 64, No. 8, 28.08.2015, p. 1057-1066.

Research output: Contribution to journalArticle

@article{a175c0381833492db4ffd5e5fc024fca,
title = "STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice",
abstract = "Therapeutic vaccines to induce anti-tumor CD8 T cells have been used in clinical trials for advanced melanoma patients, but the clinical response rate and overall survival time have not improved much. We believe that these dismal outcomes are caused by inadequate number of antigen-specific CD8 T cells generated by most vaccines. In contrast, huge CD8 T cell responses readily occur during acute viral infections. High levels of type-I interferon (IFN-I) are produced during these infections, and this cytokine not only exhibits anti-viral activity but also promotes CD8 T cell responses. The studies described here were performed to determine whether promoting the production of IFN-I could enhance the potency of a peptide vaccine. We report that cyclic diguanylate monophosphate (c-di-GMP), which activates the stimulator of interferon genes, potentiated the immunogenicity and anti-tumor effects of a peptide vaccine against mouse B16 melanoma. The synergistic effects of c-di-GMP required co-administration of costimulatory anti-CD40 antibody, the adjuvant poly-IC, and were mediated in part by IFN-I. These findings demonstrate that peptides representing CD8 T cell epitopes can be effective inducers of large CD8 T cell responses in vaccination strategies that mimic acute viral infections.",
keywords = "CD8 T cells, Immunotherapy, Peptide vaccines, STING, Type-I interferon",
author = "Zili Wang and Esteban Celis",
year = "2015",
month = "8",
day = "28",
doi = "10.1007/s00262-015-1713-5",
language = "English (US)",
volume = "64",
pages = "1057--1066",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "8",

}

TY - JOUR

T1 - STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice

AU - Wang, Zili

AU - Celis, Esteban

PY - 2015/8/28

Y1 - 2015/8/28

N2 - Therapeutic vaccines to induce anti-tumor CD8 T cells have been used in clinical trials for advanced melanoma patients, but the clinical response rate and overall survival time have not improved much. We believe that these dismal outcomes are caused by inadequate number of antigen-specific CD8 T cells generated by most vaccines. In contrast, huge CD8 T cell responses readily occur during acute viral infections. High levels of type-I interferon (IFN-I) are produced during these infections, and this cytokine not only exhibits anti-viral activity but also promotes CD8 T cell responses. The studies described here were performed to determine whether promoting the production of IFN-I could enhance the potency of a peptide vaccine. We report that cyclic diguanylate monophosphate (c-di-GMP), which activates the stimulator of interferon genes, potentiated the immunogenicity and anti-tumor effects of a peptide vaccine against mouse B16 melanoma. The synergistic effects of c-di-GMP required co-administration of costimulatory anti-CD40 antibody, the adjuvant poly-IC, and were mediated in part by IFN-I. These findings demonstrate that peptides representing CD8 T cell epitopes can be effective inducers of large CD8 T cell responses in vaccination strategies that mimic acute viral infections.

AB - Therapeutic vaccines to induce anti-tumor CD8 T cells have been used in clinical trials for advanced melanoma patients, but the clinical response rate and overall survival time have not improved much. We believe that these dismal outcomes are caused by inadequate number of antigen-specific CD8 T cells generated by most vaccines. In contrast, huge CD8 T cell responses readily occur during acute viral infections. High levels of type-I interferon (IFN-I) are produced during these infections, and this cytokine not only exhibits anti-viral activity but also promotes CD8 T cell responses. The studies described here were performed to determine whether promoting the production of IFN-I could enhance the potency of a peptide vaccine. We report that cyclic diguanylate monophosphate (c-di-GMP), which activates the stimulator of interferon genes, potentiated the immunogenicity and anti-tumor effects of a peptide vaccine against mouse B16 melanoma. The synergistic effects of c-di-GMP required co-administration of costimulatory anti-CD40 antibody, the adjuvant poly-IC, and were mediated in part by IFN-I. These findings demonstrate that peptides representing CD8 T cell epitopes can be effective inducers of large CD8 T cell responses in vaccination strategies that mimic acute viral infections.

KW - CD8 T cells

KW - Immunotherapy

KW - Peptide vaccines

KW - STING

KW - Type-I interferon

UR - http://www.scopus.com/inward/record.url?scp=84937978529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937978529&partnerID=8YFLogxK

U2 - 10.1007/s00262-015-1713-5

DO - 10.1007/s00262-015-1713-5

M3 - Article

C2 - 25986168

AN - SCOPUS:84937978529

VL - 64

SP - 1057

EP - 1066

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 8

ER -